
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2764571/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 2018, 24, 739-748.	30.7	947
2	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nature Medicine, 2006, 12, 1397-1402.	30.7	593
3	Targeted genome editing in human repopulating haematopoietic stem cells. Nature, 2014, 510, 235-240.	27.8	517
4	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. New England Journal of Medicine, 2009, 361, 478-488.	27.0	459
5	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase l–II study. Lancet Oncology, The, 2009, 10, 489-500.	10.7	458
6	IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood, 2013, 121, 573-584.	1.4	455
7	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 2012, 119, 5697-5705.	1.4	437
8	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood, 2005, 105, 1162-1169.	1.4	435
9	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine, 2012, 18, 807-815.	30.7	398
10	T memory stem cells in health and disease. Nature Medicine, 2017, 23, 18-27.	30.7	396
11	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood, 2013, 122, 3461-3472.	1.4	306
12	Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nature Methods, 2011, 8, 861-869.	19.0	300
13	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	30.7	253
14	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
15	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
16	The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood, 2007, 109, 4708-4715.	1.4	200
17	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplantation, 2020, 55, 126-136.	2.4	196
18	Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, The, 2021, 397, 1010-1022.	13.7	196

#	Article	IF	CITATIONS
19	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood, 2003, 103, 1417-1424.	1.4	195
20	ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. Journal of Biology, 2006, 5, 14.	2.7	185
21	Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New Vectors. Human Gene Therapy, 1998, 9, 2243-2251.	2.7	178
22	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1457-1462.	7.1	172
23	Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood, 2007, 109, 4698-4707.	1.4	171
24	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	12.4	166
25	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	1.4	164
26	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Science Translational Medicine, 2015, 7, 273ra13.	12.4	160
27	IL-7 and IL-15 allow the generation of suicide gene–modified alloreactive self-renewing central memory human T lymphocytes. Blood, 2009, 113, 1006-1015.	1.4	153
28	Intraâ€arterial transplantation of <scp>HLA</scp> â€matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Molecular Medicine, 2015, 7, 1513-1528.	6.9	146
29	Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood, 2003, 102, 497-505.	1.4	142
30	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. Human Gene Therapy, 1995, 6, 813-819.	2.7	137
31	The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach. Molecular Therapy, 2007, 15, 1248-1252.	8.2	131
32	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Science Translational Medicine, 2018, 10, .	12.4	125
33	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
34	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
35	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood, 2015, 125, 2865-2874.	1.4	119
36	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	2.4	117

#	Article	IF	CITATIONS
37	Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation. Blood, 2003, 101, 1290-1298.	1.4	115
38	Temporal, quantitative, and functional characteristics of single-KIR–positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood, 2008, 112, 3488-3499.	1.4	113
39	Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood, 2006, 107, 1828-1836.	1.4	110
40	Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology, 2015, 6, 95.	3.5	102
41	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Science Translational Medicine, 2015, 7, 317ra198.	12.4	102
42	Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+and CD8+T Cells. Journal of Immunology, 2001, 166, 5250-5257.	0.8	101
43	A <scp>CD</scp> 8뱉~ Subset of <scp>CD</scp> 4+ <scp>SLAMF</scp> 7+ Cytotoxic T Cells Is Expanded in Patients With IgG4â€Related Disease and Decreases Following Glucocorticoid Treatment. Arthritis and Rheumatology, 2018, 70, 1133-1143.	5.6	87
44	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
45	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
46	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. Journal of Experimental Medicine, 2014, 211, 1363-1377.	8.5	80
47	Transcriptional Enhancers Induce Insertional Gene Deregulation Independently From the Vector Type and Design. Molecular Therapy, 2009, 17, 851-856.	8.2	79
48	Adoptive Tâ€cell therapy for cancer: The era of engineered T cells. European Journal of Immunology, 2015, 45, 2457-2469.	2.9	75
49	Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. Frontiers in Immunology, 2018, 9, 507.	4.8	73
50	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood, 2017, 130, 606-618.	1.4	71
51	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. Frontiers in Immunology, 2020, 11, 1217.	4.8	69
52	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. Journal of Clinical Investigation, 2022, 132, .	8.2	66
53	Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation. Human Gene Therapy, 2010, 21, 241-250.	2.7	63
54	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology, 2020, 11, 1689.	4.8	63

MARIA CHIARA BONINI

#	Article	IF	CITATIONS
55	Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma. Transplantation, 2008, 86, 738-744.	1.0	62
56	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Frontiers in Immunology, 2017, 8, 1444.	4.8	62
57	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61
58	A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 2001, 97, 1249-1257.	1.4	59
59	Transfection of RNA Encoding Tumor Antigens Following Maturation of Dendritic Cells Leads to Prolonged Presentation of Antigen and the Generation of High-Affinity Tumor-Reactive Cytotoxic T Lymphocytes. Molecular Therapy, 2004, 9, 757-764.	8.2	58
60	Frequency and Targeted Detection of HLA-DPB1 T Cell Epitope Disparities Relevant in Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1031-1040.	2.0	50
61	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood, 2012, 120, 1820-1830.	1.4	47
62	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Science Translational Medicine, 2022, 14, eabg3072.	12.4	47
63	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunological Reviews, 2014, 257, 165-180.	6.0	46
64	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	5.3	43
65	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. Blood, 2012, 119, 4813-4815.	1.4	42
66	IL-7 receptor expression identifies suicide gene–modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood, 2011, 117, 6469-6478.	1.4	40
67	High-Definition Mapping of Retroviral Integration Sites Defines the Fate of Allogeneic T Cells After Donor Lymphocyte Infusion. PLoS ONE, 2010, 5, e15688.	2.5	39
68	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. Oncolmmunology, 2015, 4, e1005460.	4.6	37
69	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. Biology of Blood and Marrow Transplantation, 2016, 22, 2250-2255.	2.0	36
70	Genetic Modification of T Cells. Biology of Blood and Marrow Transplantation, 2011, 17, S15-S20.	2.0	30
71	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Current Opinion in Hematology, 2012, 19, 427-433.	2.5	30
72	Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates. Blood, 2012, 120, 4191-4191.	1.4	28

#	Article	IF	CITATIONS
73	CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade. Arthritis and Rheumatology, 2020, 72, 565-575.	5.6	27
74	A dual role for genetically modified lymphocytes in cancer immunotherapy. Trends in Molecular Medicine, 2012, 18, 193-200.	6.7	26
75	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2021, 27, 776.e1-776.e13.	1.2	26
76	Concomitant Tumor and Minor Histocompatibility Antigen–Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. Cancer Research, 2010, 70, 3505-3514.	0.9	25
77	Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation. Human Gene Therapy, 2011, 22, 829-841.	2.7	25
78	Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1 ⁺ Acute Myeloid Leukemia. Human Gene Therapy, 2013, 24, 220-237.	2.7	24
79	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. Molecular Therapy, 2013, 21, 466-475.	8.2	23
80	CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Science Translational Medicine, 2022, 14, eabg8027.	12.4	21
81	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
82	Inflammation Converts Human Mesoangioblasts Into Targets of Alloreactive Immune Responses: Implications for Allogeneic Cell Therapy of DMD. Molecular Therapy, 2014, 22, 1342-1352.	8.2	20
83	Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers. Frontiers in Immunology, 2013, 4, 71.	4.8	18
84	Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. Frontiers in Immunology, 2021, 12, 772239.	4.8	18
85	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. Frontiers in Pharmacology, 2015, 6, 76.	3.5	17
86	Therapeutic and Diagnostic Applications of Minor Histocompatibility Antigen HA-1 and HA-2 Disparities in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey of Different Populations. Biology of Blood and Marrow Transplantation, 2006, 12, 95-101.	2.0	16
87	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood, 2005, 105, 3596-3604.	1.4	15
88	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. Human Gene Therapy, 2015, 26, 220-231.	2.7	15
89	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American Journal of Hematology, 2017, 92, 1011-1019.	4.1	14
90	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy, 2018, 20, 453-460.	0.7	14

#	Article	IF	CITATIONS
91	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Current Opinion in Oncology, 2020, 32, 427-433.	2.4	13
92	Expression of HSV-TK suicide gene in primary T lymphocytes: The dog as a preclinical model. Cytokines, Cellular & Molecular Therapy, 2000, 6, 25-33.	0.3	10
93	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
94	Flow cytometry data mining by cytoChain identifiesÂdeterminants of exhaustion and stemness in TCRâ€engineered T cells. European Journal of Immunology, 2021, 51, 1992-2005.	2.9	10
95	Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology, 2020, 32, 398-407.	2.4	9
96	Application of Donor Lymphocytes Expressing a Suicide Gene for Early GVL Induction and Later Control of GVH Reactions After Bone-Marrow Transplantation. , 2005, 109, 475-486.		8
97	Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of latrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis. Seminars in Arthritis and Rheumatism, 2009, 39, 170-175.	3.4	8
98	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	2.4	8
99	Retrovirus mediated gene transduction of human T-cell subsets. Cancer Immunology, Immunotherapy, 2005, 54, 759-768.	4.2	6
100	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1548-1552.	2.4	6
101	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. Multiple Sclerosis Journal, 2022, 28, 1937-1943.	3.0	6
102	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2018, 53, 722-728.	2.4	5
103	Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT Blood, 2006, 108, 307-307.	1.4	4
104	1107. Gene Therapy Clinical Trials for Relapsed Leukemia with Infusions of the Suicide-Gene Transduced Donor Lymphocytes in Japan. Molecular Therapy, 2006, 13, S426.	8.2	3
105	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nature Communications, 2021, 12, 4844.	12.8	3
106	Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication. Blood, 2012, 120, 949-949.	1.4	3
107	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT), Blood, 2016, 128, 4599-4599.	1.4	3
108	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. Blood, 2013, 122, 142-142.	1.4	2

#	Article	IF	CITATIONS
109	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. Life Science Alliance, 2022, 5, e202101316.	2.8	2
110	When transgenes shape immunity: cancer immuneâ€gene therapy. Journal of Gene Medicine, 2012, 14, 384-385.	2.8	1
111	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. Blood, 2011, 118, 667-667.	1.4	1
112	NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL. Blood, 2020, 136, 32-33.	1.4	1
113	Potential of Gene Therapy in Bone Marrow Transplantation. BioDrugs, 1999, 11, 1-6.	4.6	0
114	The hidden (and lazy) TCR. Blood, 2009, 114, 2855-2856.	1.4	0
115	Trick to treat: tricking the thymus to treat cancer. Blood, 2013, 122, 304-306.	1.4	Ο
116	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia Blood, 2010, 116, 3764-3764.	1.4	0
117	An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. Blood, 2015, 126, 1929-1929.	1.4	Ο
118	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. Blood, 2015, 126, 4362-4362.	1.4	0
119	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. Blood, 2015, 126, 5465-5465.	1.4	0
120	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. Blood, 2015, 126, 263-263.	1.4	0